These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22030444)

  • 21. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
    Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
    Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
    Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
    Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
    Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
    Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.
    Sonesson C; Johansson PA; Johnsson E; Gause-Nilsson I
    Cardiovasc Diabetol; 2016 Feb; 15():37. PubMed ID: 26895767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
    Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
    J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor.
    Yamada H; Ohira H; Ikegami F; Nakamura K; Takahashi A; Abe K; Inano A; Shimada S; Miyata K; Saito T; Ohba Y; Terao K; Ohnishi A
    Drug Res (Stuttg); 2020 Sep; 70(9):401-409. PubMed ID: 32707593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
    Fioretto P; Mansfield TA; Ptaszynska A; Yavin Y; Johnsson E; Parikh S
    Drugs Aging; 2016 Jul; 33(7):511-22. PubMed ID: 27357173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
    Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
    Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dapagliflozin for the treatment of type 2 diabetes.
    Anderson SL; Marrs JC
    Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin for the treatment of type 2 diabetes.
    Brooks AM; Thacker SM
    Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Gardin A; Zaehringer A; Dodman A; Su Z; Legangneux E
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):41-53. PubMed ID: 27443658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects.
    Kasichayanula S; Liu X; Zhang W; Pfister M; Reele SB; Aubry AF; LaCreta FP; Boulton DW
    Diabetes Obes Metab; 2011 Aug; 13(8):770-3. PubMed ID: 21435141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.